Trademark: 87195766
Word
EXCIVA
Status
Registered
Status Code
700
Status Date
Tuesday, July 5, 2022
Serial Number
87195766
Registration Number
6782565
Registration Date
Tuesday, July 5, 2022
Mark Type
4000
Filing Date
Thursday, October 6, 2016
Published for Opposition
Tuesday, September 19, 2017

Trademark Owner History
EXCIVA LLC - Original Registrant
EXCIVA UG (haftungsbeschränkt) - Owner At Publication

Classifications
5 Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Trademark Events
Jul 5, 2022
Notice Of Registration Confirmation Emailed
Jul 5, 2022
Registered-Principal Register
Jun 2, 2022
Notice Of Acceptance Of Statement Of Use E-Mailed
Jun 1, 2022
Allowed Principal Register - Sou Accepted
Jun 1, 2022
Teas/Email Correspondence Entered
Jun 1, 2022
Correspondence Received In Law Office
May 28, 2022
Assigned To Lie
May 25, 2022
Teas Request For Reconsideration Received
Feb 15, 2022
Notification Of Final Refusal Emailed
Feb 15, 2022
Final Refusal E-Mailed
Feb 15, 2022
Su - Final Refusal - Written
Jan 21, 2022
Teas/Email Correspondence Entered
Jan 20, 2022
Correspondence Received In Law Office
Jan 20, 2022
Teas Response To Office Action Received
Oct 7, 2021
Notification Of Non-Final Action E-Mailed
Oct 7, 2021
Non-Final Action E-Mailed
Oct 7, 2021
Su - Non-Final Action - Written
Sep 14, 2021
Statement Of Use Processing Complete
Aug 31, 2021
Iu Informal Response Received
Aug 31, 2021
Teas Statement Of Use Received
Aug 31, 2021
Case Assigned To Intent To Use Paralegal
Aug 31, 2021
Use Affidavit Failed Formalities
Aug 25, 2021
Use Amendment Filed
Aug 31, 2021
Case Assigned To Intent To Use Paralegal
Aug 28, 2021
Teas Post Publication Amendment Received
Aug 28, 2021
Itu Office Action Issued For Statement Of Use
Aug 28, 2021
Case Assigned To Intent To Use Paralegal
Aug 25, 2021
Teas Statement Of Use Received
May 11, 2021
Noa E-Mailed - Sou Required From Applicant
Mar 29, 2021
Ttab Release Case To Trademarks
Mar 29, 2021
Opposition Terminated No. 999999
Mar 29, 2021
Board Decision Counterclaim Denied
Mar 29, 2021
Assigned To Examiner
Mar 25, 2021
Opposition Dismissed No. 999999
Jul 29, 2020
Assignment Of Ownership Not Updated Automatically
Jul 5, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jul 5, 2020
Teas Change Of Correspondence Received
Jul 5, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jul 5, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jul 5, 2020
Teas Change Of Owner Address Received
Aug 7, 2019
Assignment Of Ownership Not Updated Automatically
Apr 3, 2018
Teas Change Of Correspondence Received
Jan 17, 2018
Opposition Instituted No. 999999
Oct 17, 2017
Extension Of Time To Oppose Received
Sep 27, 2017
Teas Change Of Correspondence Received
Sep 26, 2017
Teas Change Of Correspondence Received
Sep 19, 2017
Official Gazette Publication Confirmation E-Mailed
Sep 19, 2017
Published For Opposition
Aug 30, 2017
Notification Of Notice Of Publication E-Mailed
Aug 12, 2017
Approved For Pub - Principal Register
Jul 24, 2017
Teas/Email Correspondence Entered
Jul 24, 2017
Correspondence Received In Law Office
Jul 18, 2017
Assigned To Lie
Jun 11, 2017
Teas Request For Reconsideration Received
May 26, 2017
Teas Change Of Correspondence Received
May 1, 2017
Notification Of Final Refusal Emailed
May 1, 2017
Final Refusal E-Mailed
May 1, 2017
Final Refusal Written
Apr 27, 2017
Teas/Email Correspondence Entered
Apr 27, 2017
Correspondence Received In Law Office
Apr 27, 2017
Teas Response To Office Action Received
Jan 14, 2017
Notification Of Non-Final Action E-Mailed
Jan 14, 2017
Non-Final Action E-Mailed
Jan 14, 2017
Non-Final Action Written
Jan 13, 2017
Assigned To Examiner
Oct 13, 2016
New Application Office Supplied Data Entered In Tram
Oct 10, 2016
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24